Barclays’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$164M Sell
423,616
-415,284
-50% -$154M 0.03% 358
2026
Q1
$246M Buy
838,900
+460,014
+121% +$151M 0.06% 243
2025
Q4
$133M Sell
378,886
-175,435
-32% -$59.3M 0.03% 389
2025
Q3
$179M Sell
554,321
-39,953
-7% -$12.4M 0.04% 325
2025
Q2
$231M Buy
594,274
+90,842
+18% +$36.5M 0.05% 240
2025
Q1
$219M Buy
503,432
+54,352
+12% +$21.8M 0.06% 229
2024
Q4
$166M Sell
449,080
-172,004
-28% -$72M 0.05% 266
2024
Q3
$323M Sell
621,084
-368,538
-37% -$197M 0.09% 170
2024
Q2
$536M Sell
989,622
-35,466
-3% -$18.7M 0.16% 85
2024
Q1
$532M Sell
1,025,088
-209,835
-17% -$104M 0.18% 94
2023
Q4
$582M Buy
1,234,923
+142,245
+13% +$65.8M 0.21% 78
2023
Q3
$476M Sell
1,092,678
-170,723
-14% -$77.4M 0.3% 62
2023
Q2
$561M Buy
1,263,401
+437,225
+53% +$202M 0.36% 52
2023
Q1
$380M Buy
826,176
+46,111
+6% +$21.9M 0.17% 65
2022
Q4
$400M Buy
780,065
+327,413
+72% +$166M 0.18% 79
2022
Q3
$206M Buy
452,652
+104,400
+30% +$50M 0.22% 94
2022
Q2
$168M Sell
348,252
-134,530
-28% -$66.6M 0.1% 154
2022
Q1
$237M Sell
482,782
-169,204
-26% -$77.3M 0.19% 121
2021
Q4
$302M Buy
651,986
+21,222
+3% +$8.93M 0.11% 151
2021
Q3
$235M Buy
630,764
+115,734
+22% +$44M 0.11% 153
2021
Q2
$197M Buy
515,030
+59,614
+13% +$22.8M 0.09% 178
2021
Q1
$163M Buy
455,416
+81,965
+22% +$26.4M 0.09% 187
2020
Q4
$120M Buy
373,451
+58,659
+19% +$18M 0.06% 237
2020
Q3
$84.5M Buy
314,792
+57,016
+22% +$15.3M 0.05% 266
2020
Q2
$67.8M Sell
257,776
-23,270
-8% -$6.21M 0.05% 265
2020
Q1
$63.8M Sell
281,046
-191,373
-41% -$52.2M 0.05% 254
2019
Q4
$143M Sell
472,419
-93,463
-17% -$25.7M 0.08% 202
2019
Q3
$136M Sell
565,882
-74,406
-12% -$20.4M 0.09% 191
2019
Q2
$181M Buy
640,288
+136,580
+27% +$37.3M 0.11% 152
2019
Q1
$145M Buy
503,708
+131,700
+35% +$38.1M 0.1% 161
2018
Q4
$97.7M Sell
372,008
-47,569
-11% -$13.1M 0.08% 195
2018
Q3
$115M Sell
419,577
-66,956
-14% -$17.4M 0.08% 182
2018
Q2
$116M Sell
486,533
-129,719
-21% -$30M 0.1% 165
2018
Q1
$135M Buy
616,252
+150,039
+32% +$35.2M 0.1% 164
2017
Q4
$105M Buy
466,213
+121,716
+35% +$25.9M 0.09% 191
2017
Q3
$65.4M Sell
344,497
-70,697
-17% -$13.5M 0.07% 230
2017
Q2
$78.1M Sell
415,194
-17,444
-4% -$3.13M 0.08% 179
2017
Q1
$71.5M Buy
432,638
+165,733
+62% +$26.4M 0.08% 187
2016
Q4
$38.4M Buy
266,905
+9,829
+4% +$1.32M 0.04% 341
2016
Q3
$32.2M Sell
257,076
-173,856
-40% -$22.4M 0.04% 375
2016
Q2
$56.6M Buy
430,932
+144,214
+50% +$19.7M 0.07% 229
2016
Q1
$39.6M Buy
286,718
+51,358
+22% +$6.86M 0.06% 269
2015
Q4
$32.7M Buy
235,360
+67,099
+40% +$9.24M 0.04% 393
2015
Q3
$23.6M Sell
168,261
-147,658
-47% -$22.2M 0.03% 526
2015
Q2
$51.8M Sell
315,919
-58,532
-16% -$9.35M 0.06% 285
2015
Q1
$57.7M Buy
374,451
+36,218
+11% +$5.16M 0.07% 274
2014
Q4
$42.3M Sell
338,233
-134,796
-28% -$16.7M 0.04% 409
2014
Q3
$56.3M Sell
473,029
-776
-0.2% -$89K 0.05% 291
2014
Q2
$50.7M Sell
473,805
-105,079
-18% -$10.8M 0.05% 308
2014
Q1
$57.3M Sell
578,884
-127,531
-18% -$11.5M 0.06% 259
2013
Q4
$65M Buy
706,415
+65,292
+10% +$5.8M 0.07% 263
2013
Q3
$53.2M Buy
641,123
+72,763
+13% +$6.24M 0.06% 275
2013
Q2
$46.5M Buy
+568,360
New +$42.5M 0.06% 280

Other funds holding ELV

Barclays's ELV Position: Q2 2026 in Review

Barclays reduced its Elevance Health (ELV) stake by 50% in Q2 2026, selling an estimated $154M and leaving 423,616 shares worth $164M. The position accounts for 0.03% of the portfolio, ranked #358.

Barclays first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $582M in Q4 2023. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Barclays held 423,616 shares of Elevance Health worth $164M as of Q2 2026.
  • Barclays sold 415,284 Elevance Health shares in Q2 2026, an estimated $154M.
  • Elevance Health made up 0.03% of Barclays's portfolio in Q2 2026, its #358 holding.
  • Barclays first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Elevance Health position peaked at $582M in Q4 2023.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.